​
​

Elevation Oncology (ELEV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ELEV Stock Forecast

Elevation Oncology stock forecast is as follows: an average price target of $9.00 (represents a 1593.32% upside from ELEV’s last price of $0.53) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

ELEV Price Target

The average price target for Elevation Oncology (ELEV) is $9.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $8.00. This represents a potential 1593.32% upside from ELEV's last price of $0.53.

ELEV Analyst Ratings

Buy

According to 5 Wall Street analysts, Elevation Oncology's rating consensus is 'Buy'. The analyst rating breakdown for ELEV stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Elevation Oncology Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 31, 2024Biren AminPiper Sandler$10.00$4.07145.70%1781.47%
May 13, 2024Sudan LoganathanStephens$8.00$3.54125.99%1405.17%
Row per page
Go to

The latest Elevation Oncology stock forecast, released on May 31, 2024 by Biren Amin from Piper Sandler, set a price target of $10.00, which represents a 145.70% increase from the stock price at the time of the forecast ($4.07), and a 1781.47% increase from ELEV last price ($0.53).

Elevation Oncology Price Target by Period

1M3M12M
# Anlaysts--2
Avg Price Target--$9.00
Last Closing Price$0.53$0.53$0.53
Upside/Downside-100.00%-100.00%1593.32%

In the current month, the average price target of Elevation Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Elevation Oncology's last price of $0.53. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Aug 06, 2024Cowen & Co.BuyBuyHold
Jun 28, 2024Cowen & Co.BuyBuyHold
Jun 28, 2024Piper SandlerOverweightOverweightHold
Jun 03, 2024Piper SandlerOverweightOverweightHold
May 31, 2024Piper Sandler-OverweightInitialise
May 13, 2024Stephens-OverweightInitialise
May 30, 2023Telsey Advisory-OutperformUpgrade
May 30, 2023MoffettNathanson-OutperformUpgrade
Row per page
Go to

Elevation Oncology's last stock rating was published by Cowen & Co. on Aug 06, 2024. The company gave ELEV a "Buy" rating, the same as its previous rate.

Elevation Oncology Financial Forecast

Elevation Oncology Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Elevation Oncology's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ELEV's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Elevation Oncology EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict ELEV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Elevation Oncology's previous annual EBITDA (undefined) of $NaN.

Elevation Oncology Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-13.00M$-12.41M$-13.00M$-11.82M$-13.74M$-13.45M$-14.63M$-14.48M$-13.60M$-11.23M$-13.19M
High Forecast$-13.00M$-12.41M$-13.00M$-11.82M$-13.74M$-13.45M$-14.63M$-13.32M$-12.41M$-11.23M$-13.19M
Low Forecast$-13.00M$-12.41M$-13.00M$-11.82M$-13.74M$-13.45M$-14.63M$-15.64M$-14.19M$-11.23M$-13.19M
Surprise %-----------

Elevation Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ELEV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Elevation Oncology SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Elevation Oncology's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ELEV last annual SG&A of $NaN (undefined).

Elevation Oncology EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.22$-0.21$-0.22$-0.20$-0.23$-0.23$-0.25$-0.24$-0.23$-0.19$-0.22
High Forecast$-0.22$-0.21$-0.22$-0.20$-0.23$-0.23$-0.25$-0.23$-0.21$-0.19$-0.22
Low Forecast$-0.22$-0.21$-0.22$-0.20$-0.23$-0.23$-0.25$-0.26$-0.24$-0.19$-0.22
Surprise %-----------

According to undefined Wall Street analysts, Elevation Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ELEV previous annual EPS of $NaN (undefined).

Elevation Oncology Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.68$70.0010194.12%Buy
ELEVElevation Oncology$0.53$9.001598.11%Buy
ZURAZura Bio$3.16$10.00216.46%Buy

ELEV Forecast FAQ

Is Elevation Oncology a good buy?

Yes, according to 5 Wall Street analysts, Elevation Oncology (ELEV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of ELEV's total ratings.

What is ELEV's price target?

Elevation Oncology (ELEV) average price target is $9 with a range of $8 to $10, implying a 1593.32% from its last price of $0.531. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Elevation Oncology stock go up soon?

According to Wall Street analysts' prediction for ELEV stock, the company can go up by 1593.32% (from the last price of $0.531 to the average price target of $9), up by 1781.47% based on the highest stock price target, and up by 1405.17% based on the lowest stock price target.

Can Elevation Oncology stock reach $1?

ELEV's average twelve months analyst stock price target of $9 supports the claim that Elevation Oncology can reach $1 in the near future.

What are Elevation Oncology's analysts' financial forecasts?

Elevation Oncology's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-56.301M (high $-55.143M, low $-57.46M), average SG&A $0 (high $0, low $0), and average EPS is $-0.953 (high $-0.933, low $-0.972). ELEV's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-50.242M (high $-50.242M, low $-50.242M), average SG&A $0 (high $0, low $0), and average EPS is $-0.85 (high $-0.85, low $-0.85).